CR Double-Crane Pharmaceutical (SHA:600062) said its production facilities met the good manufacturing practice (GMP) requirements of the Beijing Municipal Medical Products Administration, according to a Friday filing with the Shanghai bourse.
The inspection covered the solid preparation workshop's hard capsule line for amlodipine besylate and benazepril hydrochloride capsules and a newly built powder line for compound polyethylene glycol electrolyte powder.
The capsule line has an annual capacity of 500 million capsules, while the powder line can produce 1.2 million bags annually.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments